AQUESTIVE THERAPEUTICS INC (AQST)
US03843E1047 - Common Stock
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
These stocks are gapping in today's session
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company...
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company...
Investors Land AQST Even Cheaper Than Its Secondary Stock Offering
A Stock Split Catalyst Looms for Chipotle (CMG) Stock on June 6
Chipotle stock is rising on Wednesday as investors in CMG shares react to the company seeking approval for a 50-for-one split.
INTC Stock Alert: Intel Just Got a Major $8.5 Billion Boost
Intel stock is rising on Wednesday as investors in INTC shares react to the semiconductor company securing $8.5 billion in funding.
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?
Aquestive Therapeutics stock is falling on Wednesday after the company price a public offering for AQST shares this morning.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out as we dive into all of the biggest movements worth reading about on Wednesday morning!
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company...
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company...
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than...
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023
AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aquestive Therapeutics (NASDAQ:AQST) just reported results for the fourth quart...
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical...
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company...